Quantifying Innovation: Three Key Signals from NHSA's Draft on New Chemical Drug Launch Pricing
The standout enhancement in the current proposal is the addition of a self-assessment scale. This tool, designed to assign a score that quantifies innovation quality based on the company's self-assessment, plays a crucial role in determining the initial pricing of their drugs.
Pudong Drug Pricing Pilot
#1 Pudong reform pilot permits new drug launch pricing comparable to international markets.
On January 22nd, a joint announcement was
Fair Pricing of Pharmaceuticals: Insights into China's NRDL Negotiation
Although NRDL negotiation involves multiple aspects, at its core, the most fundamental issue is the fair pricing of innovative pharmaceuticals.
NHSA Proposes Launch Price Framework and Aligns Pricing Policies with Drug Lifecycle
At a recent industry investor conference, Weng Linjia, Deputy Director of the Pharmaceutical Pricing and Tender Procurement Department, National Healthcare
NHSA Insurance Funding Expert Zheng Jie: Shifting from Excessive Price Reduction to Value-Based Procurement for China's Drug Pricing Dilemma
At the 5th China Rare Disease Cooperation and Exchange Conference, Zheng Jie, the leader of the Insurance Funding Analysis Expert
Wonder Sir Founder Chen Yiwei on China’s Rare Disease Definition and Recent Policy Boost for Foreign CGT Investment
Motivated by a profound sense of purpose and deeply moved by the suffering of Chinese rare disease patients, Chen Yiwei,
China Implements More Moderate and Predictable Price Reduction for Older NRDL-Negotiated Drugs
In late June, the National Healthcare Security Administration (NHSA) commenced the 2023 National Reimbursement Drug List (NRDL) Dynamic Update, aiming
Navigating China's Access Landscape for Orphan Therapies: Insights into Funding Pathways
Welcome back to the final installment of our three-part series exploring China's access landscape of rare disease therapies.
